azacitidine

May 20, 2012

Three Late-Stage Leukemia Company Previews for ASCO

May 8, 2011 By MD Becker Partners 1 Comment

blood_slide

Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.

Filed Under: Articles Tagged With: Acute myelogenous leukemia, AML, azacitidine, CALGB, Cancer and Leukemia Group B, CELG, Celgene Corporation, CYCC, Cyclacel Pharmaceuticals, cytarabine, DACO-016, Dacogen, Daruka Mahadevan, decitabine, Eisai Co, ESALF, JNJ, Johnson & Johnson, sapacitabine, SEAMLESS, SNSS, special protocol assessment, Sunesis Pharmaceuticals, SuperGen, SUPG, VALOR, Vidaza, vosaroxin

Investment Opportunities with Five Frontline Therapies for AML

September 6, 2010 By MD Becker Partners 2 Comments

473462-small

Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow. Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet. In AML, abnormal blasts produce white blood cells that do not function [...]

Filed Under: Articles Tagged With: AC220, Acute myelogenous leukemia, Ambit Biosciences, AML, AraC, Astellas Pharma, azacitidine, blasts, CD33 receptor, CELG, Celgene, CEPH, Cephalon, clofarabine, Clolar, CYCC, Cyclacel Pharmaceuticals, cytarabine, Dacogen, daunorubicin, decitabine, Eisai, ESALF, farnesyltransferase inhibitors, FDA, Food and Drug Administration, gemtuzumab ozogamicin, GENZ, Genzyme Corporation, hypomethylating agents, idarubicin, JNJ, Johnson & Johnson, laromustine, lestaurtinib, lintuzumab, monoclonal antibodies, Mylotarg, nucleoside analogs, Onrigin, PFE, Pfizer, Sanofi-Aventis, sapacitabine, Seattle Genetics, SGEN, SNSS, SNY, SPA, special protocol assessment, sunesis, SuperGen, SUPG, tipifarnib, topoisomerase II inhibitors, Vidaza, Vion Pharmaceuticals, voreloxin, vosaroxin, Zarnestra

Gut Check Time for GVHD Companies: BMT Tandem Meetings Review

February 28, 2010 By MD Becker Partners 2 Comments

1764831-smallslide

The 2010 BMT Tandem Meetings were held in Orlando, Florida this past week [February 24-28, 2010]. Considered the premier event for hematopoietic cell transplantation [HCT] and cellular therapy, the annual event attracts more than 2,500 clinicians, transplant nurses, clinical research professionals, data managers, pharmacists, center administrators and mid-level practitioners. With more than 200 abstracts being [...]

Filed Under: Articles Tagged With: azacitidine, BMT InfoNet, BMT Tandem Meetings, CELG, Celgene, Graft-versus-Host disease, GVHD, hematopoietic cell transplantation, mesenchymal stem cells, oral beclomethasone, orBec, OSIR, Osiris Therapeutics, Prochymal, Sigma-Tau Pharmaceuticals, SNGX, Soligenix, ursodeoxycholic acid, Vidaza